BioScience Managers – Page 12 – BioScience Managers

Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19

7th September 2020/in BioScience Managers

Link to Full Article Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19 SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment Innovate UK grant of £800,000 to support SPOR-COV™ programme over the next 18 months […]

New industry Advisory Group Chairs appointed AusBiotech

3rd September 2020/in BioScience Managers

Link to Full Article AusBiotech welcomes its new industry Advisory Group Chairs: Dr Megan Robertson, St Vincent’s Hospital Melbourne, Chair of the AusBiotech Clinical Trials Adivsory Group; and Dr Amanda Gillon, Bioscience Managers, Chair of the AusBiotech Investor Advisory Group. AusBiotech’s national advisory groups and state branch committees are important mechanisms to highlight and address […]

Destiny Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today

17th August 2020/in BioScience Managers

Link to Full Article Destiny Pharma, as an NBIC industrial partner, is currently working on three NBIC funded research projects in collaboration with expert teams at the Universities of Cardiff, Sheffield and Southampton. The XF drug platform has demonstrated efficacy against bacteria in biofilms and we are looking forward to advancing these research assets towards […]

Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update

13th August 2020/in BioScience Managers

Link to Full Article MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the second quarter of 2020 and provided a corporate and clinical update. During the […]

Destiny Pharma’s positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections

11th August 2020/in BioScience Managers

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections Brighton, United Kingdom – 11 August 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]

Destiny Pharma’s Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections

27th July 2020/in BioScience Managers

Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]

Congenica Automation Further Accelerates Identification of Genetic Diseases

15th July 2020/in BioScience Managers

Link to Full Article Cambridge, United Kingdom – 15 July 2020 – Congenica has launched Congenica Automation, an update for its clinical decision support platform that will provide automated classification, evidence and reporting of recurrent ‘known’ variants that customers observe in their rare disease cases, significantly saving time while maximizing diagnostic yield and laboratory throughput. The key […]

Pharma companies join forces to launch $1 billion fund to develop new antibiotics 2030

10th July 2020/in BioScience Managers

Link to Full Article Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. The AMR Action Fund, aims to bring 2-4 new antibiotics to patients 2030. Through the AMR Action Fund, pharmaceutical companies will join […]

UK patent office issued the Microscaffold patent (GB2544748A)

23rd June 2020/in BioScience Managers

Link to Full Article On 23 June 2020, the UK patent office issued the Microscaffold patent (GB2544748A). Our custom Microscaffolds can be made from a large variety of materials and sizes, tailored towards their desired application. Their open, porous, three-dimensional structure allows for facile cell attachment and integration over a large range of cell types. These scaffolds […]

Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections

17th June 2020/in BioScience Managers

Link to Full Article Non-dilutive funding to be used to advance the company’s second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today […]

Pages